SG11201807834WA - Bridged bicyclic inhibitors of menin-mll and methods of use - Google Patents
Bridged bicyclic inhibitors of menin-mll and methods of useInfo
- Publication number
- SG11201807834WA SG11201807834WA SG11201807834WA SG11201807834WA SG11201807834WA SG 11201807834W A SG11201807834W A SG 11201807834WA SG 11201807834W A SG11201807834W A SG 11201807834WA SG 11201807834W A SG11201807834W A SG 11201807834WA SG 11201807834W A SG11201807834W A SG 11201807834WA
- Authority
- SG
- Singapore
- Prior art keywords
- huron
- floor
- international
- ann arbor
- parkway
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662309362P | 2016-03-16 | 2016-03-16 | |
US201662431387P | 2016-12-07 | 2016-12-07 | |
PCT/US2017/022535 WO2017161002A1 (en) | 2016-03-16 | 2017-03-15 | Bridged bicyclic inhibitors of menin-mll and methods of use |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201807834WA true SG11201807834WA (en) | 2018-10-30 |
Family
ID=59851929
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201807834WA SG11201807834WA (en) | 2016-03-16 | 2017-03-15 | Bridged bicyclic inhibitors of menin-mll and methods of use |
Country Status (17)
Country | Link |
---|---|
US (2) | US10752639B2 (de) |
EP (1) | EP3429585B1 (de) |
JP (1) | JP7000333B2 (de) |
KR (1) | KR102419524B1 (de) |
CN (1) | CN109640987B (de) |
AU (1) | AU2017235462B2 (de) |
BR (1) | BR112018068702A2 (de) |
CA (1) | CA3015845A1 (de) |
HK (1) | HK1258821A1 (de) |
IL (1) | IL261625B (de) |
MA (1) | MA43823A (de) |
MX (1) | MX2018011092A (de) |
PH (1) | PH12018501955A1 (de) |
SG (1) | SG11201807834WA (de) |
TW (1) | TWI743096B (de) |
WO (1) | WO2017161002A1 (de) |
ZA (1) | ZA201805845B (de) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016040330A1 (en) | 2014-09-09 | 2016-03-17 | The Regents Of The University Of Michigan | Thienopyrimidine and thienopyridine compounds and methods of use thereof |
EP3302057A4 (de) | 2015-06-04 | 2018-11-21 | Kura Oncology, Inc. | Verfahren und zusammensetzungen zur hemmung der interaktion von menin mit mll-proteinen |
TWI703150B (zh) | 2015-06-04 | 2020-09-01 | 美商庫拉腫瘤技術股份有限公司 | 用於抑制menin及mll蛋白之交互作用的方法及組合物 |
IL261606B (en) | 2016-03-16 | 2022-09-01 | Kura Oncology Inc | Inhibitors of converted menin-mll and methods of use |
MA43823A (fr) | 2016-03-16 | 2018-11-28 | Kura Oncology Inc | Inhibiteurs bicycliques pontés de ménine-mll et méthodes d'utilisation |
CA3022868A1 (en) | 2016-05-02 | 2017-11-09 | Shaomeng Wang | Piperidines as menin inhibitors |
EP3512857B1 (de) | 2016-09-14 | 2021-02-24 | Janssen Pharmaceutica NV | Spiro-bizyklische inhibitoren von menin-mll-wechselwirkung |
EP3512858B1 (de) | 2016-09-14 | 2023-11-08 | Janssen Pharmaceutica NV | Kondensierte bicyclische inhibitoren der menin-mll-interaktion |
AU2017376599B2 (en) | 2016-12-15 | 2021-10-07 | Janssen Pharmaceutica Nv | Azepane inhibitors of menin-MLL interaction |
EA201991448A1 (ru) | 2017-01-06 | 2019-12-30 | Янссен Фармацевтика Нв | Азепановые ингибиторы взаимодействия менин-mll |
US11944627B2 (en) * | 2017-03-24 | 2024-04-02 | Kura Oncology, Inc. | Methods for treating hematological malignancies and Ewing's sarcoma |
MX2019011412A (es) | 2017-03-31 | 2020-02-07 | Univ Michigan Regents | Piperidinas como inhibidores de menina covalentes. |
US11542248B2 (en) | 2017-06-08 | 2023-01-03 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
TW201920170A (zh) * | 2017-09-20 | 2019-06-01 | 美商庫拉腫瘤技術股份有限公司 | 經取代之menin-mll 抑制劑及使用方法 |
US11396517B1 (en) | 2017-12-20 | 2022-07-26 | Janssen Pharmaceutica Nv | Exo-aza spiro inhibitors of menin-MLL interaction |
CN110204552B (zh) * | 2018-02-28 | 2021-08-17 | 中国科学院上海药物研究所 | 一类噻吩并[3,2-d]嘧啶衍生物、其制备方法、药物组合物与用途 |
US11325921B2 (en) | 2018-03-30 | 2022-05-10 | Sumitomo Dainippon Pharma Co., Ltd. | Optically active crosslinked cyclic secondary amine derivative |
EP3856173A4 (de) * | 2018-09-26 | 2022-07-06 | Kura Oncology, Inc. | Behandlung hämatologischen malignitäten mit inhibitoren von menin |
CN110964016B (zh) * | 2018-09-29 | 2021-05-28 | 南京药捷安康生物科技有限公司 | 氨基降茨烷衍生物及其制备方法与应用 |
SG11202104243VA (en) * | 2018-12-06 | 2021-05-28 | Daiichi Sankyo Co Ltd | Cycloalkane-1,3-diamine derivative |
TW202043205A (zh) | 2018-12-31 | 2020-12-01 | 美商拜歐米富士恩有限公司 | Menin-mll相互作用之抑制劑 |
CN111297863B (zh) * | 2020-03-30 | 2021-06-25 | 四川大学华西医院 | menin-MLL抑制剂在制备治疗子宫内膜癌的药物中的应用 |
US20230165858A1 (en) * | 2020-04-07 | 2023-06-01 | Syndax Pharmaceuticals, Inc. | Combinations of menin inhibitors and cyp3a4 inhibitors and methods of use thereof |
CN117321049A (zh) | 2021-05-08 | 2023-12-29 | 詹森药业有限公司 | 取代的螺环衍生物 |
EP4334320A1 (de) | 2021-05-08 | 2024-03-13 | JANSSEN Pharmaceutica NV | Substituierte spiroderivate |
AR125866A1 (es) | 2021-05-14 | 2023-08-23 | Syndax Pharmaceuticals Inc | Inhibidores de la interacción de menina-mll |
EP4347588A1 (de) | 2021-06-01 | 2024-04-10 | JANSSEN Pharmaceutica NV | Substituierte phenyl-1h-pyrrolo[2,3-c pyridin-derivate |
CN117425659A (zh) | 2021-06-03 | 2024-01-19 | 詹森药业有限公司 | 哒嗪或被螺环胺取代的1,2,4-三嗪 |
KR20240021808A (ko) | 2021-06-17 | 2024-02-19 | 얀센 파마슈티카 엔브이 | 암과 같은 질환의 치료를 위한 (r)-n-에틸-5-플루오로-n-아이소프로필-2-((5-(2-(6-((2-메톡시에틸)(메틸)아미노)-2-메틸헥산-3-일)-2,6-다이아자스피로[3.4]옥탄-6-일)-1,2,4-트라이아진-6-일)옥시)벤즈아미드 베실레이트 염 |
WO2023220098A1 (en) * | 2022-05-09 | 2023-11-16 | Syndax Pharmaceuticals, Inc. | Menin-mll inhibitors for the treatment of cancer |
Family Cites Families (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US510A (en) | 1837-12-07 | soeel | ||
US5863A (en) | 1848-10-17 | Matthias p | ||
US949A (en) | 1838-09-27 | Improvement in roller cotton-gins for ginning long-staple and other kinds of cotton | ||
US5861A (en) | 1848-10-17 | Locking umbrella and parasol | ||
US1007727A (en) | 1908-02-17 | 1911-11-07 | Oscar F Onken | Auxiliary table-top. |
US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
DE4239169A1 (de) | 1992-11-21 | 1994-05-26 | Merck Patent Gmbh | Cyclobutan - Benzol - Derivate |
US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
EP0821671B1 (de) | 1995-04-20 | 2000-12-27 | Pfizer Inc. | Arylsulfonamido-substituierte hydroxamsäure derivate als inhibitoren von mmp und tnf |
DK0780386T3 (da) | 1995-12-20 | 2003-02-03 | Hoffmann La Roche | Matrixmetalloproteaseinhibitorer |
JP3195756B2 (ja) | 1996-07-04 | 2001-08-06 | 公子 吉水 | 潤滑補助体 |
EP0923585B1 (de) | 1996-07-18 | 2002-05-08 | Pfizer Inc. | Matrix metalloprotease-inhibitoren auf basis von phosphinsäuren |
JP3333870B2 (ja) | 1996-07-26 | 2002-10-15 | 国土交通省北陸地方整備局長 | 草刈機 |
JP2000501423A (ja) | 1996-08-23 | 2000-02-08 | ファイザー インク. | アリールスルホニルアミノヒドロキサム酸誘導体 |
US5866562A (en) | 1996-10-25 | 1999-02-02 | Bayer Aktiengesellschaft | Ring-bridged bis-quinolines |
PT950059E (pt) | 1997-01-06 | 2004-10-29 | Pfizer | Derivados de sulfona ciclicos |
ID22799A (id) | 1997-02-03 | 1999-12-09 | Pfizer Prod Inc | Turunan-turunan asam arilsulfonilamino hidroksamat |
JP2000507975A (ja) | 1997-02-07 | 2000-06-27 | ファイザー・インク | N−ヒドロキシ−β−スルホニルプロピオンアミド誘導体類及びそれらのマトリックスメタロプロテイナーゼ阻害薬としての使用 |
IL131123A0 (en) | 1997-02-11 | 2001-01-28 | Pfizer | Arylsulfonyl hydroxamic acid derivatives |
JPH10330377A (ja) | 1997-06-02 | 1998-12-15 | Kyowa Hakko Kogyo Co Ltd | ピペリジン誘導体 |
GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
US6479487B1 (en) | 1998-02-26 | 2002-11-12 | Aventis Pharmaceuticals Inc. | 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines |
PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
PA8474101A1 (es) | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
WO2002088107A1 (en) | 2001-04-26 | 2002-11-07 | Eisai Co., Ltd. | Nitrogenous fused-ring compound having pyrazolyl group as substituent and medicinal composition thereof |
CN100343258C (zh) | 2001-04-30 | 2007-10-17 | 美国拜尔公司 | 新的4-氨基-5,6-取代的噻吩并[2,3-d]嘧啶化合物 |
WO2003022214A2 (en) | 2001-09-06 | 2003-03-20 | Millennium Pharmaceuticals, Inc. | Piperazine and homopiperazine compounds |
WO2004030671A2 (en) | 2002-10-02 | 2004-04-15 | Merck Patent Gmbh | Use of 4-amino-quinazolines as anti cancer agents |
AU2003255482A1 (en) | 2002-10-02 | 2004-04-23 | Merck Patent Gmbh | Use of 4 amino-quinazolines as anti cancer agents |
US20050222175A1 (en) | 2004-03-31 | 2005-10-06 | Dhanoa Dale S | New piperidinylamino-thieno[2,3-D] pyrimidine compounds |
NZ542236A (en) | 2003-03-31 | 2008-05-30 | Predix Pharmaceuticals Holding | New piperidinylamino-thieno[2,3-d]pyrimidine compounds |
US7612078B2 (en) | 2003-03-31 | 2009-11-03 | Epix Delaware, Inc. | Piperidinylamino-thieno[2,3-D] pyrimidine compounds |
US8362264B2 (en) | 2003-08-22 | 2013-01-29 | Dendreon Corporation | Compositions and methods for the treatment of disease associated with Trp-p8 expression |
US20050123906A1 (en) | 2003-11-06 | 2005-06-09 | Rana Tariq M. | Protein modulation |
EP1768964A1 (de) | 2004-07-06 | 2007-04-04 | Angion Biomedica Corporation | Chinazolinmodulatoren des hepatozytenwachstumsfaktors/der c-met-aktivität für die behandlung von krebs |
US7553964B2 (en) * | 2005-06-03 | 2009-06-30 | Abbott Laboratories | Cyclobutyl amine derivatives |
US20060281769A1 (en) | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using thienopyrimidine and thienopyridine kinase modulators |
US20060281771A1 (en) | 2005-06-10 | 2006-12-14 | Baumann Christian A | Synergistic modulation of flt3 kinase using aminoquinoline and aminoquinazoline kinase modulators |
EP1937272A2 (de) | 2005-09-02 | 2008-07-02 | Tibotec Pharmaceuticals Ltd. | Benzodiazepine als hcv-hemmer |
EP1926798B1 (de) | 2005-09-19 | 2009-09-30 | Merck Patent GmbH | Cyclobutan- und spiro[3.3]heptanverbindungen |
FR2891829A1 (fr) | 2005-10-12 | 2007-04-13 | Sanofi Aventis Sa | Derives de la 4-amino-quinazoline, leur preparation et leur application en therapeutique |
WO2007076034A2 (en) | 2005-12-21 | 2007-07-05 | Abbott Laboratories | Anti-viral compounds |
EP2004656B1 (de) | 2006-04-07 | 2013-07-10 | Boehringer Ingelheim International GmbH | Thienopyrimidine mit mnk1/mnk2-hemmender wirkung für pharmazeutische zusammensetzungen |
EP1903044A1 (de) | 2006-09-14 | 2008-03-26 | Novartis AG | Adenosinderivate als Agonisten des A2A-Rezeptors |
US8242078B2 (en) * | 2006-10-19 | 2012-08-14 | The University Of Chicago | Therapeutics to inhibit MLL-menin interaction for treating leukemia |
EP1947103A1 (de) | 2007-01-22 | 2008-07-23 | 4Sc Ag | Aryloxypropanolamine, Herstellungsverfahren dafür und Verwendung von Aryloxypropanolaminen als Arzneimittel |
WO2008099019A1 (en) | 2007-02-16 | 2008-08-21 | Tibotec Pharmaceuticals Ltd. | 6-hydroxy-dibenzodiazepinones useful as hepatitis c virus inhibitors |
FR2913017A1 (fr) | 2007-02-23 | 2008-08-29 | Cerep Sa | Derives de piperidine et piperazine comme agents anti-neoplasiques ou inhibiteurs de proliferation cellulaire |
ATE496022T1 (de) | 2007-03-19 | 2011-02-15 | Council Scient Ind Res | Anthranilsäure-derivat als antikrebswirkstoff und verfahren zur herstellung davon |
WO2008135232A1 (en) | 2007-05-02 | 2008-11-13 | Riccardo Cortese | Use and compositions of purine derivatives for the treatment of proliferative disorders |
WO2008153760A1 (en) | 2007-05-25 | 2008-12-18 | Burnham Institute For Medical Research | Inhibitors of thapsigargin-induced cell death |
WO2009017838A2 (en) | 2007-08-01 | 2009-02-05 | Exelixis, Inc. | Combinations of jak-2 inhibitors and other agents |
WO2009064388A2 (en) | 2007-11-09 | 2009-05-22 | Liu Jun O | Inhibitors of human methionine aminopeptidase 1 and methods of treating disorders |
CA2709784A1 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
CN102105463A (zh) | 2008-05-22 | 2011-06-22 | 阿勒根公司 | 对cxcr4受体有活性的二环化合物 |
DE102008027574A1 (de) | 2008-06-10 | 2009-12-17 | Merck Patent Gmbh | Neue Pyrrolidinderivate als MetAP-2 Inhibitoren |
KR101354763B1 (ko) | 2008-08-25 | 2014-01-22 | 아이알엠 엘엘씨 | 헷지호그 경로 조절제 |
WO2010030757A2 (en) | 2008-09-10 | 2010-03-18 | Kalypsys Inc. | Aminopyrimidine inhibitors of histamine receptors for the treatment of disease |
JP5690823B2 (ja) | 2009-07-08 | 2015-03-25 | レオ ファーマ アクティーゼルスカブ | Jak受容体およびタンパク質チロシンキナーゼ阻害薬としての複素環化合物 |
US8742100B2 (en) | 2009-07-30 | 2014-06-03 | National University Of Singapore | Small molecule inhibitors of isoprenylcysteine carboxyl methyltransferase with potential anticancer activity |
CA2773131C (en) | 2009-09-04 | 2015-07-14 | The Regents Of The University Of Michigan | Compositions and methods for treatment of leukemia |
WO2011101069A2 (en) | 2010-02-22 | 2011-08-25 | Merck Patent Gmbh | Hetarylaminonaphthyridines |
WO2012022265A1 (en) | 2010-08-20 | 2012-02-23 | Hutchison Medipharma Limited | Pyrrolopyrimidine compounds and uses thereof |
US9090624B2 (en) * | 2011-08-04 | 2015-07-28 | Allergan, Inc. | Aromatic bycyclic derivatives as CXCR4 receptor modulators |
GB201114212D0 (en) | 2011-08-18 | 2011-10-05 | Ucb Pharma Sa | Therapeutic agents |
AR090037A1 (es) | 2011-11-15 | 2014-10-15 | Xention Ltd | Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio |
CN103833759A (zh) * | 2012-11-23 | 2014-06-04 | 华东理工大学 | 作为blk、flt3抑制剂的蝶啶酮衍生物及其应用 |
EP2968285A4 (de) | 2013-03-13 | 2016-12-21 | Flatley Discovery Lab | Verbindungen und verfahren zur behandlung von zystischer fibrose |
BR112015022602A2 (pt) * | 2013-03-13 | 2017-07-18 | Univ Michigan Regents | composições compreendendo compostos de tienopirimidina e tienopiridina e métodos de uso dos mesmos |
US9212180B2 (en) * | 2013-06-12 | 2015-12-15 | The Regents Of The University Of Michigan | Menin-MLL inhibitors and methods of use thereof |
EP3489232A3 (de) * | 2014-04-04 | 2019-07-31 | Syros Pharmaceuticals, Inc. | Hemmer der cyclinabhängigen kinase 7 (cdk7) |
US20170119769A1 (en) * | 2014-06-10 | 2017-05-04 | The Trustees Of The University Of Pennsylvania | Scaffolds for inhibitors of menin-mll interactions |
WO2016040330A1 (en) | 2014-09-09 | 2016-03-17 | The Regents Of The University Of Michigan | Thienopyrimidine and thienopyridine compounds and methods of use thereof |
TWI703150B (zh) | 2015-06-04 | 2020-09-01 | 美商庫拉腫瘤技術股份有限公司 | 用於抑制menin及mll蛋白之交互作用的方法及組合物 |
EP3302057A4 (de) | 2015-06-04 | 2018-11-21 | Kura Oncology, Inc. | Verfahren und zusammensetzungen zur hemmung der interaktion von menin mit mll-proteinen |
CN108779116A (zh) | 2015-12-22 | 2018-11-09 | 生命医药公司 | 多发性内分泌瘤蛋白-mll相互作用的抑制剂 |
WO2017132398A1 (en) | 2016-01-26 | 2017-08-03 | Memorial Sloan-Kettering Cancer Center | Targeting chromatin regulators inhibits leukemogenic gene expression in npm1 mutant leukemia |
MA43823A (fr) | 2016-03-16 | 2018-11-28 | Kura Oncology Inc | Inhibiteurs bicycliques pontés de ménine-mll et méthodes d'utilisation |
IL261606B (en) | 2016-03-16 | 2022-09-01 | Kura Oncology Inc | Inhibitors of converted menin-mll and methods of use |
CA3022868A1 (en) | 2016-05-02 | 2017-11-09 | Shaomeng Wang | Piperidines as menin inhibitors |
WO2017207387A1 (en) | 2016-05-31 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction |
MX2018015252A (es) | 2016-06-10 | 2019-04-25 | Vitae Pharmaceuticals Inc | Inhibidores de la interaccion de menina-leucemia de linaje mixto. |
WO2018024602A1 (en) | 2016-08-04 | 2018-02-08 | Bayer Aktiengesellschaft | 2,7-diazaspiro[4.4]nonanes |
EP3512858B1 (de) | 2016-09-14 | 2023-11-08 | Janssen Pharmaceutica NV | Kondensierte bicyclische inhibitoren der menin-mll-interaktion |
CA3033239A1 (en) | 2016-09-14 | 2018-03-22 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-mll interaction |
EP4230627A3 (de) | 2016-09-16 | 2023-11-15 | Vitae Pharmaceuticals, LLC | Inhibitoren der menin-mll-interaktion |
-
2017
- 2017-03-15 MA MA043823A patent/MA43823A/fr unknown
- 2017-03-15 SG SG11201807834WA patent/SG11201807834WA/en unknown
- 2017-03-15 CA CA3015845A patent/CA3015845A1/en active Pending
- 2017-03-15 JP JP2018544323A patent/JP7000333B2/ja active Active
- 2017-03-15 MX MX2018011092A patent/MX2018011092A/es unknown
- 2017-03-15 KR KR1020187029700A patent/KR102419524B1/ko active IP Right Grant
- 2017-03-15 TW TW106108619A patent/TWI743096B/zh active
- 2017-03-15 EP EP17767444.7A patent/EP3429585B1/de active Active
- 2017-03-15 US US16/082,645 patent/US10752639B2/en active Active
- 2017-03-15 AU AU2017235462A patent/AU2017235462B2/en active Active
- 2017-03-15 BR BR112018068702A patent/BR112018068702A2/pt not_active Application Discontinuation
- 2017-03-15 CN CN201780030449.4A patent/CN109640987B/zh active Active
- 2017-03-15 WO PCT/US2017/022535 patent/WO2017161002A1/en active Application Filing
-
2018
- 2018-08-30 ZA ZA2018/05845A patent/ZA201805845B/en unknown
- 2018-09-05 IL IL261625A patent/IL261625B/en unknown
- 2018-09-11 PH PH12018501955A patent/PH12018501955A1/en unknown
-
2019
- 2019-01-23 HK HK19101198.7A patent/HK1258821A1/zh unknown
-
2020
- 2020-07-13 US US16/927,844 patent/US11555041B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CA3015845A1 (en) | 2017-09-21 |
AU2017235462A1 (en) | 2018-09-27 |
JP7000333B2 (ja) | 2022-02-10 |
JP2019508426A (ja) | 2019-03-28 |
KR20180127406A (ko) | 2018-11-28 |
US20210107917A1 (en) | 2021-04-15 |
ZA201805845B (en) | 2023-03-29 |
MX2018011092A (es) | 2018-11-22 |
US10752639B2 (en) | 2020-08-25 |
MA43823A (fr) | 2018-11-28 |
CN109640987A (zh) | 2019-04-16 |
TW201742870A (zh) | 2017-12-16 |
CN109640987B (zh) | 2022-12-02 |
EP3429585A4 (de) | 2019-10-09 |
EP3429585A1 (de) | 2019-01-23 |
TWI743096B (zh) | 2021-10-21 |
AU2017235462B2 (en) | 2021-07-01 |
WO2017161002A1 (en) | 2017-09-21 |
KR102419524B1 (ko) | 2022-07-08 |
HK1258821A1 (zh) | 2019-11-22 |
PH12018501955A1 (en) | 2019-06-17 |
BR112018068702A2 (pt) | 2019-01-15 |
US11555041B2 (en) | 2023-01-17 |
IL261625A (en) | 2018-10-31 |
US20190092783A1 (en) | 2019-03-28 |
IL261625B (en) | 2021-08-31 |
EP3429585B1 (de) | 2021-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201807834WA (en) | Bridged bicyclic inhibitors of menin-mll and methods of use | |
SG11201807982UA (en) | Substituted inhibitors of menin-mll and methods of use | |
SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
SG11201900677SA (en) | Combination therapies of chimeric antigen receptors adn pd-1 inhibitors | |
SG11201808196UA (en) | Neoantigens and methods of their use | |
SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
SG11201810983PA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
SG11201808907PA (en) | Inhibitors of activin receptor-like kinase | |
SG11201907840RA (en) | Fused imidazo-piperidine jak inhibitors | |
SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
SG11201808678QA (en) | Macrocyclic inhibitors of the pd-1/pd-l1 and cd80/pd-l1 protein/protein interactions | |
SG11201808990QA (en) | Compositions for topical application of compounds | |
SG11201900480YA (en) | Anti-tim-3 antibodies | |
SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
SG11201807426WA (en) | Immunomodulators | |
SG11201907451XA (en) | Substituted imidazo-quinolines as nlrp3 modulators | |
SG11201804098TA (en) | Purinones as ubiquitin-specific protease 1 inhibitors | |
SG11201805645QA (en) | Lsd1 inhibitors | |
SG11201810927QA (en) | Pd-l1-specific antibodies and methods of using the same | |
SG11201806251WA (en) | Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody | |
SG11201809751XA (en) | Egfr inhibitor compounds | |
SG11201806282XA (en) | High-throughput identification of patient-specific neoepitopes as therapeutic targets for cancer immunotherapies | |
SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
SG11201908602UA (en) | Combination therapy for the treatment of solid and hematological cancers |